Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cannabis Poland's EBITDA for the
three
months ended in Mar. 2026 was €-0.17 Mil. Cannabis Poland's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Cannabis Poland's EBITDA margin for the quarter that ended in Mar. 2026 was -4,150.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cannabis Poland EBITDA Margin % Related Terms
Cannabis Poland EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cannabis Poland's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8TE vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Poland's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Poland EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannabis Poland's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cannabis Poland's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Poland (FRA:8TE) has a EBITDA Margin % of -4,150.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannabis Poland and its competitors. According to the industry distribution chart, Cannabis Poland ranks #930 out of 961 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Cannabis Poland's EBITDA Margin % too high?
Cannabis Poland's current EBITDA Margin % is -4,150.00%. Based on the distribution chart, Cannabis Poland ranks #930 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cannabis Poland has a GF Score™ of 26/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannabis Poland's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannabis Poland ranks #930 out of 961 companies for EBITDA Margin %. This places Cannabis Poland in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannabis Poland and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Poland's current EBITDA Margin % is -4,150.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Poland stock overvalued right now?
Based on GuruFocus' analysis, Cannabis Poland (FRA:8TE) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.02, compared to a current price of €0.02 — trading 12.5% above its estimated fair value. The current EBITDA Margin % is -4,150.00%. Cannabis Poland's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cannabis Poland (FRA:8TE), the current EBITDA Margin % is -4,150.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannabis Poland (FRA:8TE) Overvalued in 2026?
Based on GuruFocus' analysis, Cannabis Poland stock appears to be overvalued.
The current stock price of €0.02 is trading 12.5% above its estimated GF Value™ of €0.02.
GuruFocus considers Cannabis Poland to be Modestly Overvalued.
Key valuation signals for FRA:8TE:
EBITDA Margin %: -4,150.00%
GF Value™: €0.02 vs. price of €0.02 (12.5% above fair value)
No single metric tells the full story. See the FRA:8TE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8TE has been successfully added to your 
